Through the work of the Immune Effector Cell Task Force, led by Co-Chairs Dr. Helen Heslop, Dr. EJ Shpall, and Dr. Michael Lill, FACT has published proposed interim standards for the sixth edition FACT-JACIE International Standards for Hematopoietic Cellular Therapy Collection, Processing, and Administration. The interim standards are intended to promote quality in administration of immune effector cell products, such as chimeric antigen receptor T cells (CAR-T cells), natural killer cells, virus-specific T cells, therapeutic cellular vaccines, and others. The proposed requirements primarily highlight unique aspects of administration and toxicities of immune effector cells. They are open for public comment through September 9, 2016.

It is important for all accredited programs to be aware of these proposed interim standards, to review them, and to make comments and suggestions during this public comment period. Thank you in advance for participating in this important peer-review process to maintain Standards that are relevant and useful to our field.

Comments may be submitted online through September 9, 2016.

Proposed Interim Immune Effector Cell Standards
Frequently Asked Questions
Public Comment Form

Ask FACT

FAQ

Ask a Peer
FACT Consulting

Accreditation Success Story

Hoxworth Blood Center Apheresis Collection Facility and its Cellular Therapies Division have been accredited by FACT since 2003. The program values their FACT accreditation and the impact it has had on their program’s continuous quality improvement objectives. Read more